T he novel pH1N1 influenza A virus was first noted in North America in March 2009, and by July 2009, 43,677 cases were reported in the United States (1) . World Health Organization data indicate an estimate of 16,713 deaths worldwide (2). Estimates suggest that 7-31% of patients with pH1N1 requiring hospitalization require care in an intensive care unit (ICU) (3) (4) (5) (6) . Mortality in patients infected with pH1N1 who require ICU care has been estimated to be 7-41% (3) (4) (5) (6) . Previous studies have identified several independent risk factors for severe disease requiring ICU admission, including underlying lung disease (7-10), obesity (7, 10, 11) , pregnancy (8) , and race (7, 10) .
Management guidelines for acute respiratory distress syndrome (ARDS) associated with pH1N1 have been focused on lung protective ventilation and are not necessarily specific to the pH1N1 patient population. The Australian and New Zealand Intensive Care Influenza Investigators reported their experience with extracorporeal membranous oxygenation (ECMO) as rescue therapy in patients with pH1N1 with severe ARDS (11) . Survival with the use of ECMO in the Australian and New Zealand Intensive Care Influenza was 79%. Regional differences in use of ECMO likely exist and, to date, reports of the efficacy of ECMO in North America during the pH1N1 epidemic are very limited. In one publication from Canada, the ECMO survival rate for refractory hypoxemia for pH1N1 influenza infection was 67%. However, this report described Objective: Severe respiratory failure is a well-recognized complication of pH1N1 influenza infection. Limited data regarding the efficacy of rescue therapies, including high-frequency oscillatory ventilation and extracorporeal membrane oxygenation, have been previously reported in the setting of pH1N1 influenza infection in the United States.
Design: Retrospective, single-center cohort study. Setting: Pediatric, cardiac, surgical, and medical intensive care units in a single tertiary care center in the United States.
Patients: One hundred twenty-seven consecutive patients with confirmed influenza A infection requiring hospitalization between April 1, 2009, and October 31, 2009.
Interventions: Electronic medical records were reviewed for demographic and clinical data.
Measurements and Main Results: The number of intensive care unit admissions appears inversely related to age with 39% of these admissions <20 yrs of age. Median duration of intensive care unit care was 10.0 days (4.0 -24.0), and median duration of mechanical ventilation was 8.0 days (0.0 -23.5). Rescue therapy (high-frequency oscillatory ventilation or extracorporeal membrane oxygenation) was used in 36% (12 of 33) of intensive care unit patients. The severity of respiratory impairment was determined by PaO 2 /FIO 2 ratio and oxygenation index. High-frequency oscillatory ventilation at 24 hrs re- Extracorporeal membrane oxygenation resulted in anticipated improvement in parameters of oxygenation at both 2 hrs and 24 hrs after initiation of therapy. Despite the severity of oxygenation impairment, overall survival for both rescue therapies was 75% (nine of 12), 80% (four of five) for high-frequency oscillatory ventilation alone, and 71% (five of seven) for highfrequency oscillatory ventilation ؉ extracorporeal membrane oxygenation.
Conclusion: In critically ill adult and pediatric patients with pH1N1 infection and severe lung injury, the use of high-frequency oscillatory ventilation and extracorporeal membrane oxygenation can result in significant improvements in PaO 2 /FIO 2 ratio, oxygenation index, and FIO 2 . However, the impact on mortality is less certain. (Crit Care Med 2010; 38:2103-2107) KEY WORDs: influenza; acute respiratory distress syndrome; pH1N1; mechanical ventilation; high-frequency oscillatory ventilation; extracorporeal membrane oxygenation (ECMO); hypoxemia; respiratory failure; lung injury only six patients across four centers (12) . Similar reports of limited patient populations, including early data from the University of Michigan in July 2009 (13), demonstrated mortality of 30% for ten patients who required surgical ICU admission for consideration of ECMO. Additionally, it remains unclear whether other rescue therapies, including high-frequency oscillatory ventilation (HFOV), offer significant benefit. Therefore, we report our experience with ECMO and HFOV in the treatment of adults and children with pH1N1 influenza infection.
PATIENTS AND METHODS
Study Design. This was a single-center retrospective study of infants, children, and adults conducted at a tertiary care center in the United States. The study was reviewed and approved by the Duke University Institutional Review Board with waiver of informed consent.
Patient Selection and Data Collection. All patients admitted to Duke University Medical Center between April 1, 2009, and October 31, 2009, with either confirmed or probable pH1N1 were included in the analysis. Confirmed cases include patients with influenza A with confirmation of pH1N1 genotype by polymerase chain reaction performed at the North Carolina State Reference Laboratory. Probable case of pH1N1 was defined as confirmed influenza A not further subtyped. However, Ͼ99% of tested influenza A isolates in North Carolina during the period of enrollment were pH1N1.
We identified 127 pediatric and adult patients with confirmed or probable pH1N1. Acute Physiology and Chronic Health Evaluation (APACHE) II score was calculated using the worst values for the 24-hr period after initial admission to an ICU. For patients who required vasopressor support, the mean arterial pressure was defined to be Յ40 mm Hg. Patients who had previously been awake but who required heavy sedation or paralysis for mechanical ventilation were judged to have a Glasgow Coma Score of 10. Mean airway pressure, FIO 2 , and PaO 2 were additionally documented at the time of initiation of ECMO or HFOV. Ն30 cm H 2 O and FIO 2 Ն0.50 on conventional ventilation in the setting of bilateral infiltrates consistent with ARDS and/or the presence of significant air leak. Patients were considered candidates for ECMO when their oxygenation index (OI) during HFOV exceeded 40 for greater than 2-4 hrs for the adult patients and 4 -6 hrs for the pediatric patients. Contraindications for ECMO included documented irreversible brain injury or multisystem organ failure, underlying malignancy with limited life expectancy, and/or unresponsive septic shock (the latter being a relative contraindication only). There is no policy regarding specific clinical contraindications to HFOV at our facility. After initiation of HFOV, all persons entering the patient room used N-95 or surgical masks. We are not aware of any transmission of pH1N1 in our hospital with this protocol.
Some patients received multiple modalities of rescue therapy during their hospitalization. Data from each initiation of rescue modality were included in the analysis. If a patient did not have data available at the specific time point, data were collected closest to the goal time point within the following parameters: 2 hrs before (1-6 hrs), 2 hrs after (1-6 hrs), and 24 hrs after (12-36 hrs). If multiple values existed, the value closest to the goal time point was reported. All patients on ECMO were cannulated as venovenous with exception of one pediatric patient (child with underlying congenital heart disease) who received venoarterial ECMO.
Statistical Analysis. Descriptive statistics are presented as median (interquartile range). Significant differences between groups were identified using the Wilcoxon rank-sum test using SPSS (Chicago, IL) and GraphPad (San Diego, CA) software. A two-tailed p value of Ͻ.05 was considered statistically significant.
RESULTS

Characteristics of Patients With pH1N1 (Confirmed or Probable)
Requiring ICU Care. We identified 127 patients hospitalized with pH1N1 infection between April 1, 2009, and October 31, 2009. Forty-six percent (58 of 127) of the patients admitted to the hospital with pH1N1 were under the age of 18. During the enrollment period, 33 patients with pH1N1 infection required ICU care with a peak in ICU admissions and mortality during the month of September (Fig. 1 ). There was a relatively high prevalence of black patients who required ICU care (57% [19 of 33] as compared with a 38% black distribution in the local community) ( Table 1 ). The majority of the patients who required ICU care had significant comorbid medical conditions (94% [31 of 33]). There was an inverse relationship between decade of life and number of patients admitted to the ICU (Fig. 2) . Thirty-nine percent (13 of 33) of patients admitted to the ICU were under 20 years of age. The duration of care for subjects in our cohort include hospitalization 18.0 days (7.3-30.5 days), ICU care 10.0 days (4.0 -24.0 days), and mechanical ventilation 8.0 days (0 -23.5 days).
Patients with pH1N1 on ECMO required significantly more blood products when compared with other ICU patients with pH1N1. During the enrollment period, patients on ECMO received more units of packed red blood cells with a median of 21 units (16 - Patients With pH1N1 With ARDS and Rescue Therapy. All patients requiring mechanical ventilation were ventilated with a low tidal-volumes strategy as per the ARDS Network recommendations (14) . In terms of other adjunct therapies, 58% (19 of 33) of all patients who required ICU care received steroids, whereas 27% (nine of 33) of the study population received inhaled nitric oxide. In patients who were eventually cannulated for ECMO, 86% (six of seven) received steroids and/or inhaled nitric oxide, whereas 40% of the patients who received only HFOV as rescue therapy received steroids and/or inhaled nitric oxide. Forty-three percent (three of seven) of patients on ECMO developed acute renal failure and required hemodialysis. Hemoconcentration was not otherwise used in management of these patients. Recruitment maneuvers and prone positioning were not used for patients on conventional ventilation, although recruitment maneuvers were performed through a standardized protocol for patients requiring HFOV.
Rescue therapy (defined as HFOV or ECMO) was used in 36% (12 of 33) of the ICU patients in our study population. Patients receiving rescue therapy were evenly distributed between pediatrics and adult populations. For all patients receiving HFOV, there were 5 pediatric (range, 0 -17 yrs) and 7 adult (range, 18 -51 yrs) patients. For the subset of patients on HFOV whom eventually required ECMO, there were 3 pediatric (range, 0 -17) and 4 adult (range, 18-33 yrs) patients. Three patients (25%) received HFOV more than once during the course of their hospital course, and all patients who were placed on ECMO received HFOV. The median duration of rescue therapy was 4.5 days (2.0 -17 days) for HFOV and 10.0 days (8.0 -28.0 days) for ECMO. The seven patients who were placed on ECMO underwent HFOV for a median duration of 6 days (range, 0 -15 days) before cannulation. While on ECMO, all patients were transitioned to conventional ventilation as tolerated using lungprotective strategies, including low tidal volume ventilation (6 mL/kg). Patients receiving rescue therapy had a median length of hospital stay of 35.0 days (22.0 -39.0 days), whereas ICU patients who received standard supportive care remained in the hospital a median of 10.0 days (5.0 -22.0 days; p ϭ .001). The median length of ICU stay for patients receiving rescue therapy was 24.0 days (14.0 -38.0 days) compared with 5.0 days (3.0 -9.0 days) for ICU patients receiving standard supportive care (p Ͻ .001).
Mortality Associated With pH1N1. The overall survival for patients hospitalized with confirmed or probable pH1N1 was 93.7% (119 of 127) (Fig. 5) . The median APACHE II score for all patients receiving ICU care was 16 (13) (14) (15) (16) (17) (18) (19) (20) with an overall survival of 75% (25 of 33) during the study period. The overall survival for ICU patients who did and did not require rescue therapy was 75% (nine of 12) and 76% (16 of 21), respectively. Patients receiving ECMO had a median APACHE II of 19.0 (13.0 -23.0) with an overall survival of 71.4% (five of seven) ( Table 2 ). In addition, all patients receiving rescue therapy had APACHE II scores between 10 and 24 with three patients having an APACHE II between 20 and 24, all of whom received ECMO.
All deaths occurred in the setting of withdrawal of care. Of the three patients who received rescue therapy and died, withdrawal occurred in the setting of: 1) massive pulmonary hemorrhage as a result of Gram-negative septic shock, which prompted the need for ECMO; 2) refractory hypoxemia and inability to be decannulated after a 38-day ECMO course; and 3) refractory hypoxemia on HFOV complicated by underlying hematologic malignancy and Tamiflu-resistant pH1N1. Of the eight patients who died during the study period, two had an APACHE II of 12 or 13 (including both patients on ECMO), three between 17 and 21, and the remaining three Ն25. Two of the patients who died and were not offered rescue therapy had active malignancy, one had a cerebrovascular accident, which was diagnosed during admission, and the other two had multiorgan system failure and families who stated they would not want aggressive care. In addition to severity of lung injury, overall mortality in this cohort was associated with presence of comorbidities and drug-resistant pH1N1 genotype. The H275Y mutation, which has been associated with putative resistance to oseltami-vir, was found in 12% (four of 33) of the ICU patients' pH1N1 isolates. Three (75%) individuals infected with this variant of pH1N1 did not survive to hospital discharge. The fourth patient with the H275Y mutation was discharged to hospice care and subsequently died at home.
DISCUSSION
pH1N1 influenza infection required significant critical care resources, especially in a small subset of patients with refractory ARDS. Despite lengthy support with HFOV and/or ECMO, overall survival was quite good (Fig. 5) given the extreme severity of respiratory illness. This review of our adult and pediatric data lends support to the use of these rescue approaches in patients with severe pH1N1 respiratory failure. This is the first such comprehensive report in the United States, and our ECMO survival data approximate that published from the Australia/New Zealand and Canadian experiences.
Critical care resources were required in 26% (33 of 127) of hospitalized patients with pH1N1 influenza infection (confirmed or probable). The majority of patients requiring care in an ICU setting had significant comorbid medical conditions previously associated with severe pH1N1 infection. pH1N1 infection requiring any ICU care was associated with a prolonged duration of hospitalization and mechanical ventilator support. Rescue therapy was used in 36% (12 of 33) of these ICU patients with respiratory failure.
Although HFOV has been used in pediatric populations since the 1980s, studies of HFOV use in ARDS have failed to demonstrate statistically significant benefit over conventional ventilation to date (15, 16) . Results from the Canadian trial evaluating HFOV in ARDS, although not yet available, may provide more insight. Recent literature regarding management of ARDS in pH1N1 notes that consideration should be given to the use of HFOV for refractory hypoxemia when available (17) . At our center, where HFOV is used routinely in both the adult and pediatric populations, the implementation of HFOV resulted in significant improvements in PaO 2 /FIO 2 ratio, OI, and FIO 2 . Overall survival with the use of HFOV alone was 80% (four of five) and with HFOV followed by ECMO was 71% (five of seven). These findings echo the results of the recent Conventional ventilatory support versus Extracorporeal membrane oxygenation for Severe Adult Respiratory failure (CESAR) publication in terms of the success of ECMO for adult refractory hypoxemia (18) .
Recent experience in Utah (7) demonstrated overall survival of 83% of patients requiring ICU care (73% in adult patients with ARDS), none of whom received HFOV or ECMO. Although it is not indicated whether such modalities were available at the centers involved, it is noted that all eight deaths occurred in those patients with ARDS with mention of the fact that approximately 50% (14 of 30) of patients with ARDS had significant hypoxemia requiring substantial ventilator support (positive end expiratory pressure Ն20 cm H 2 O with FIO 2 1.0). Because additional information regarding mortality within this group is not available, it is unclear whether rescue therapies, had they been available, might have altered the outcome.
The majority of the patients who required ICU care had APACHE II scores between 10 and 24, including all those who received rescue therapy (Table 2) . Of the patients who died during the study period, only two qualified for and went on to receive ECMO; the remaining six, including one who received HFOV, had contraindications to ECMO. Interestingly, both patients who died despite ECMO therapy had the lowest APACHE II scores of their cohort (12 and 13, respectively). Neither of these patients had the H275Y mutation and one death was associated with an overwhelming secondary bacterial infection.
Conclusions from this study should be interpreted with some caution. This is a retrospective analysis of a single academic center with a high level of experience using HFOV and ECMO. Additionally, although our data clearly demonstrate benefits in oxygenation with rescue therapy, it remains unclear whether these rescue modalities actually impacted survival, although we speculate that they in fact did. Finally, rescue modalities of therapy were associated with a prolonged duration of hospitalization and ICU care and very significant resource use in terms of equipment, bed space, and staffing. The ethical consideration of these rescue therapies in the face of the limited resources of a pandemic are worthy of discussion but are beyond the scope of this report.
CONCLUSIONS
In critically ill patients with confirmed or probable H1N1 and severe ARDS, the use of HFOV and ECMO can result in significant improvements in oxygenation and may improve mortality in this very highrisk population. Thus, we feel that it is reasonable to consider these rescue modalities in refractory ARDS related to pH1N1 influenza infection in both pediatric and adult patients. The potential role of rescue modalities for severe pH1N1 should be critically examined in a randomized, controlled trial.
